Verastem, Inc. VSTM
8.18 USD -0.26 (-3.08%)
Regular-session close
7.99 -0.19 -2.32%
After hours · Nov 13, 4:13 PM ET
7.98 Day range 8.40
3.43 52-week range 10.82
- YTD
- +5.96%
- 1 year
- +0.86%
News
marketbeat.com Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path Verastem NASDAQ: VSTM plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile…
marketbeat.com Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans Verastem NASDAQ: VSTM is advancing its experimental KRAS G12D inhibitor VS-7375 toward potential accelerated approval in pancreatic cancer, with plans to expand studies in colorectal and lung…benzinga.com RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $18 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $19 to $18.
benzinga.com HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $20 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $18 to $20.
benzinga.com Verastem Oncology Q3 2026 Earnings Call Transcript Verastem Oncology (NASDAQ:VSTM) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Verastem Oncology Files $100M At-The-Market Equity Offering Agreement With Cantor Fitzgerald This registration statement contains the following documents:• a base prospectus, which covers the offering, issuance and sale by us of an indeterminate amount of the securities identified below from…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.benzinga.com Verastem Q3 Adj. EPS $(0.72) Misses $(0.46) Estimate, Sales $24.012M Miss $26.078M Estimate Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.46) by 56.52 percent. This is a 33.33 percent decrease over losses of $(0.54)…
benzinga.com Mizuho Maintains Outperform on Verastem, Raises Price Target to $14 Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $13 to $14.
benzinga.com Jefferies Maintains Buy on Verastem, Raises Price Target to $13 Jefferies analyst Faisal Khurshid maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $11 to $13.
benzinga.com RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $14 to $19.
benzinga.com Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
benzinga.com BTIG Maintains Buy on Verastem, Raises Price Target to $24 BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $18 to $24.
benzinga.com Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.
benzinga.com Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.benzinga.com Verastem Oncology Appoints Michael P. Bailey As President And CEO, Effective January 1, 2027 Mr. Bailey will also continue to serve on the Company’s Board of Directors. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and continue…
benzinga.com Verastem Oncology Announces Initial Data In First Multi-Tumor Update From Ongoing TARGET-D 101 Phase 1/2 Clinical Trial Evaluating VS-7375; Data Demonstrate Robust Clinical Activity With Favorable Safety And Tolerability Profile Across Multiple Dose Levels And Tumor Types VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a…
benzinga.com Verastem Oncology Q2 2026 Earnings Call Transcript Verastem Oncology (NASDAQ:VSTM) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
benzinga.com BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.benzinga.com HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
benzinga.com Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026 RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with…
benzinga.com HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
benzinga.com Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ETVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with…
benzinga.com Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13 Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $14 to $13.
benzinga.com Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12 Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market session. The company's market cap stands at $17.1 billion. As per the news, the Q2 earnings report came…
benzinga.com These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.
benzinga.com Earnings Scheduled For March 4, 2026
benzinga.com Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Earnings Scheduled For November 4, 2025 benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket benzinga.com Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
benzinga.com Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and…
benzinga.com Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 446 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 200 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 528 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday saw 127 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 44 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 930 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 524 stocks hit new 52-week lows.
